Ananda Ghosh, an analyst from H.C. Wainwright, maintained the Buy rating on Annexon Biosciences. The associated price target remains the same with $14.00.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Ananda Ghosh’s rating is based on Annexon Biosciences’ promising advancements in their late-stage complement inhibitors, which show significant regulatory progress. The company’s drug tanruprubart is set for an EU MAA filing in January 2026, backed by new data indicating substantial improvements in quality of life for patients with Guillain-Barré Syndrome (GBS). This data highlights the drug’s potential for rapid, disease-modifying effects, enhancing its appeal to regulators and payers.
Additionally, Annexon’s vonaprument program, aimed at preserving vision in geographic atrophy (GA), has completed its Phase 3 enrollment ahead of schedule. The trial’s focus on vision preservation as a primary endpoint, harmonized across U.S. and EU regulators, reduces regulatory risks. The support from EMA’s PRIME Product Development Coordinator pilot further strengthens the regulatory pathway, positioning vonaprument as a potential first-in-class therapy for GA. These factors collectively contribute to the Buy rating for Annexon Biosciences.
According to TipRanks, Ghosh is a 5-star analyst with an average return of 63.5% and a 79.49% success rate. Ghosh covers the Healthcare sector, focusing on stocks such as Maze Therapeutics, Inc., ProQR, and Stoke Therapeutics.
In another report released yesterday, Jefferies also maintained a Buy rating on the stock with a $10.00 price target.